CEO Buys 37,500 Zevra Shares, Boosting Confidence in Rare‑Disease Pipeline
CEO buys 37,500 shares of Zevra Therapeutics, signaling confidence in its fast‑track drug Miplyffa and boosting investor optimism.
3 minutes to read
Zevra Therapeutics Inc
Insider Sale at Zevra Highlights Confidence, Not Crisis – 3,000 Shares Sold for $9.18
Insider sale at Zevra shows cash‑flow planning, not panic—investors see a confidence boost from rising holdings while monitoring liquidity.
4 minutes to read